Cord blood platelet gel for the treatment of inherited epidermolysis bullosa

Alessandra Gelmetti, Noemi Greppi, Sophie Guez, Francesca Grassi, Paolo Rebulla, Gianluca Tadini

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The management of patients affected by epidemolysis bullosa requires an integrated approach involving different specialties. A cornerstone of clinical management is the prevention and treatment of mechanobullous ulcerations of the patient's skin, which significantly impact the quality of life and can be the cause of septic and neoplatic complications. This article describes the preliminary clinical evaluation of the use of allogeneic cord blood platelet gel, a novel blood component obtained from umbilical cord blood of healthy, term neonates, for the treatment of skin ulcers in patients with dystrophic epidermolysis bullosa. The promising clinical results obtained in this small patient group support the development of larger controlled clinical trials to compare the efficacy of platelet gel obtained from cord blood versus traditional platelet gel prepared from adult blood donors and versus current standard approaches of wound care in these patients.

Original languageEnglish
Pages (from-to)370-373
JournalTransfusion and Apheresis Science
Volume57
Issue number3
DOIs
Publication statusPublished - 2018

Fingerprint

Epidermolysis Bullosa
Fetal Blood
Blood Platelets
Gels
Epidermolysis Bullosa Dystrophica
Skin Ulcer
Controlled Clinical Trials
Therapeutics
Blood Donors
Patient Care
Quality of Life
Newborn Infant
Skin
Wounds and Injuries

Keywords

  • Epidermolysis bullosa
  • Platelet gel
  • Umbilical cord blood

ASJC Scopus subject areas

  • Hematology

Cite this

Cord blood platelet gel for the treatment of inherited epidermolysis bullosa. / Gelmetti, Alessandra; Greppi, Noemi; Guez, Sophie; Grassi, Francesca; Rebulla, Paolo; Tadini, Gianluca.

In: Transfusion and Apheresis Science, Vol. 57, No. 3, 2018, p. 370-373.

Research output: Contribution to journalArticle

@article{43ee97a87bc14b63a5e71819742957cf,
title = "Cord blood platelet gel for the treatment of inherited epidermolysis bullosa",
abstract = "The management of patients affected by epidemolysis bullosa requires an integrated approach involving different specialties. A cornerstone of clinical management is the prevention and treatment of mechanobullous ulcerations of the patient's skin, which significantly impact the quality of life and can be the cause of septic and neoplatic complications. This article describes the preliminary clinical evaluation of the use of allogeneic cord blood platelet gel, a novel blood component obtained from umbilical cord blood of healthy, term neonates, for the treatment of skin ulcers in patients with dystrophic epidermolysis bullosa. The promising clinical results obtained in this small patient group support the development of larger controlled clinical trials to compare the efficacy of platelet gel obtained from cord blood versus traditional platelet gel prepared from adult blood donors and versus current standard approaches of wound care in these patients.",
keywords = "Epidermolysis bullosa, Platelet gel, Umbilical cord blood",
author = "Alessandra Gelmetti and Noemi Greppi and Sophie Guez and Francesca Grassi and Paolo Rebulla and Gianluca Tadini",
year = "2018",
doi = "10.1016/j.transci.2018.05.021",
language = "English",
volume = "57",
pages = "370--373",
journal = "Transfusion and Apheresis Science",
issn = "1473-0502",
publisher = "Elsevier Limited",
number = "3",

}

TY - JOUR

T1 - Cord blood platelet gel for the treatment of inherited epidermolysis bullosa

AU - Gelmetti, Alessandra

AU - Greppi, Noemi

AU - Guez, Sophie

AU - Grassi, Francesca

AU - Rebulla, Paolo

AU - Tadini, Gianluca

PY - 2018

Y1 - 2018

N2 - The management of patients affected by epidemolysis bullosa requires an integrated approach involving different specialties. A cornerstone of clinical management is the prevention and treatment of mechanobullous ulcerations of the patient's skin, which significantly impact the quality of life and can be the cause of septic and neoplatic complications. This article describes the preliminary clinical evaluation of the use of allogeneic cord blood platelet gel, a novel blood component obtained from umbilical cord blood of healthy, term neonates, for the treatment of skin ulcers in patients with dystrophic epidermolysis bullosa. The promising clinical results obtained in this small patient group support the development of larger controlled clinical trials to compare the efficacy of platelet gel obtained from cord blood versus traditional platelet gel prepared from adult blood donors and versus current standard approaches of wound care in these patients.

AB - The management of patients affected by epidemolysis bullosa requires an integrated approach involving different specialties. A cornerstone of clinical management is the prevention and treatment of mechanobullous ulcerations of the patient's skin, which significantly impact the quality of life and can be the cause of septic and neoplatic complications. This article describes the preliminary clinical evaluation of the use of allogeneic cord blood platelet gel, a novel blood component obtained from umbilical cord blood of healthy, term neonates, for the treatment of skin ulcers in patients with dystrophic epidermolysis bullosa. The promising clinical results obtained in this small patient group support the development of larger controlled clinical trials to compare the efficacy of platelet gel obtained from cord blood versus traditional platelet gel prepared from adult blood donors and versus current standard approaches of wound care in these patients.

KW - Epidermolysis bullosa

KW - Platelet gel

KW - Umbilical cord blood

UR - http://www.scopus.com/inward/record.url?scp=85048833620&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048833620&partnerID=8YFLogxK

U2 - 10.1016/j.transci.2018.05.021

DO - 10.1016/j.transci.2018.05.021

M3 - Article

VL - 57

SP - 370

EP - 373

JO - Transfusion and Apheresis Science

JF - Transfusion and Apheresis Science

SN - 1473-0502

IS - 3

ER -